Gilead Sciences INC GILEAD SCIENCES ORD SHS
Gilead Sciences INC GILEAD SCIENC.../ US3755581036 /
0QYQ
24/05/2024 18:04:40
|
Var.
-
|
Volume |
Denaro18:30:00 |
Lettera18:30:00 |
Capitalizzazione di mercato |
Dividend Y. |
Rapporto P/E |
66.42USD
|
-
|
6,526 Fatturato: 96,741.02 |
-Quantità in denaro: - |
-Quantità in lettera: - |
80.58 bill.USD |
4.64% |
14.25 |
Descrizione business
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Consiglio di amministrazione & Consiglio di sorveglianza
CEO |
Daniel O’Day |
Consiglio di amministrazione |
Andrew Dickinson, Jyoti Mehra, Stacey Ma, Flavius Martin, Johanna Mercier, Johanna Mercier, Cindy Perettie, Deborah H. Telman |
Consiglio di sorveglianza |
Daniel O’Day, Jacqueline K. Barton, Jeffrey A. Bluestone, Sandra J. Horning, Kelly A. Kramer, Kevin E. Lofton, Harish Manwani, Harish Manwani, Anthony Welters |
Dati aziendali
Name: |
Gilead Sciences Inc. |
Indirizzo: |
333 Lakeside Drive,Foster City, California 94404, USA |
Telefono: |
+1-650-574-3000 |
Fax: |
+1-650-578-9264 |
E-mail: |
corporate_communicat...ead.com
corporate_communications@gilead.com
|
Internet: |
www.gilead.com |
Industria: |
Healthcare |
Settore: |
Pharmaceutical Industry |
Sub settore: |
Pharmaceuticals |
Fine dell'anno finanziario: |
31/12 |
Flottante libero: |
55.84% |
Data dell'IPO: |
22/01/1992 |
Company calendar
CW 26 | 27/06/2024
Dividend Payment
|
CW 32 | 08/08/2024
Interim Report 2nd Quarter/6 Months
|